Anuh Pharma (ANUHPHR) — concall transcript

📢 Key Event
Anuh Pharma reported FY22 revenue of ₹491 crores, up 11.5% YoY with 22.4% operating margin and EBITDA of ₹52 crores.

🔄 What Changed
Revenue grew 11.5% YoY to ₹491 crores; EBITDA reached ₹52 crores; capacity utilization at 60% with plans to add 300 tons; FY23 revenue target set at ₹600 crores.

🔮 What's Next
Target FY23 revenue of ₹600 crores; plans to add 300 tons capacity; launch five new products including Allopurinol and Acebrophylline; CAPEX of ₹40-50 lakhs; focus on expanding in Vietnam, Japan, and South Korea; CEP filings for Gliclazide, Azithromycin, and WHO PQ for Isoniazide to enable European and institutional sales.

💡 Investor Takeaway
Management is targeting ₹600 crores revenue for FY23 through new product launches and geographic expansion, but faces challenges in achieving this amid current demand and institutional shareholder concerns.

Anuh Pharma reported FY22 revenue of ₹491 crores, up 11.5% YoY with 22.4% operating margin and EBITDA of ₹52 crores. Capacity utilization stands at 60% of 1500 tons, with plans to add 300 tons. Management targets ₹600 crores revenue for FY23, driven by new API launches and expansion in Vietnam, Japan, and South Korea. They aim to increase market share of existing products and leverage CEP approvals for Gliclazide, Azithromycin, and WHO PQ for Isoniazide to unlock European and institutional sales. Capex of [amount context mismatch]-50 lakhs is planned for FY23 to enhance versatility. Demand is expected to improve post-pandemic, especially in antibiotics during monsoon season. Shareholding remains 70.43% with promoters and 29.57% retail, with no institutional holdings confirmed.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ANUHPHR ✨ Ask AI About This

About Anuh Pharma Ltd (ANUHPHR)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹896.2 Cr P/E: 20.3 ROE: 12.5% ROCE: 17.2% Div Yield: 1.68%

View full ANUHPHR stock details →

📡 Get AI alerts when ANUHPHR files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ANUHPHR — Free

💡 Ask AI about this filing

"What is the timeline for CEP approvals to unlock European market sales?" "How will the ₹40-50 lakh CAPEX be allocated across new product launches?" "When will institutional shareholding be confirmed and what is the strategy to address retail investor concerns?"

Ask AI Free →

📊 More ANUHPHR filings

See all ANUHPHR filings →

🔥 Also filed on 31 March 2022

M&M Mahindra & Mahindra Ltd concall transcript INFY Infosys Ltd concall transcript ASIANPAINT Asian Paints Ltd concall transcript RELIANCE Reliance Industries Ltd concall transcript TATASTEEL Tata Steel Ltd concall transcript HDFCBANK HDFC Bank Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ANUHPHR files new disclosures

Track ANUHPHR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ANUHPHR — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd